ANAPTYSBIO, INC (ANAB) Stock
6 of the hedge funds AlphaScala tracks reported ANAB in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $54.49M. Company insiders reported 0 open-market buys and 1 sale on SEC Form 4 in the 90 days to Oct 21, 2026.
Which hedge funds own ANAB?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 807K | $54.49M | +70% |
| D.E. Shaw David Shaw | 540K | $36.43M | -7% |
| Citadel Ken Griffin | 394K | $26.62M | +69% |
| Renaissance Technologies Jim Simons (founder) | 58K | $3.94M | -36% |
| Marshall Wace | 44K | $2.96M | -36% |
| Hussman Investment Trust John Hussman | 21K | $1.42M | n/a |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are ANAPTYSBIO, INC insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 1, 26 | Renton Hollings | Director | SELL | 5.0K | $249K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →ANAB price chart
Powered by TradingViewWhat does ANAPTYSBIO, INC do?
AnaptysBio Inc. is a clinical-stage biotechnology company focused on developing innovative immunology therapeutics for autoimmune and inflammatory diseases. It advances antibody-based drug candidates that modulate immune pathways, including rosnilimab, a PD-1 agonist and pathogenic T cell depleter studied in rheumatoid arthritis; ANB033, a CD122 antagonist in trials for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator; and ANB032, a BTLA agonist for atopic dermatitis. The company has discovered and out-licensed therapeutic antibodies through financial collaborations, such as Jemperli (dostarlimab-gxly), a PD-1 antagonist to GSK for oncology indications, and imsidolimab, an IL-36 receptor antagonist to Vanda Pharmaceuticals for generalized pustular psoriasis. These partnerships provide eligibility for milestone payments and royalties. AnaptysBio Inc. maintains biopharma operations centered on internal clinical programs alongside its royalty-generating assets. Headquartered in San Diego, California, since 2005, it plays a key role in the immunology sector by targeting immune cell modulation to address unmet needs in autoimmune conditions.